Laidback Al
Well-known member
Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness
September 2011
The development of representative candidate influenza vaccine viruses, coordinated by WHO, remains an essential component of the overall global strategy for pandemic preparedness. Comparisons of the candidate vaccine viruses with respect to antigenicity and their relationship to newly emerging viruses are ongoing and will be periodically reported by WHO. An update of current and completed vaccine clinical trials can be found on the WHO web site.1
Influenza A(H5N1)
Since their re-emergence in 2003, highly pathogenic avian influenza A(H5N1) vi ruses have become enzootic in some coun tries and continue to cause outbreaks in poultry as well as sporadic human infections. The A(H5N1) viruses have diversified both genetically and antigenically leading to the need for multiple candidate vaccine viruses for pandemic prepared ness purposes. This summary provides updates on the characterization of A(H5N1) viruses isolated from birds and humans, and the current status of the development of candidate A(H5N1) vaccine viruses.
Influenza A(H5N1) activity:
16 February-19 September 2011
A{H5NI) viruses have been detected in birds in Africa, Asia, and the Middle East. Human infections have been reported to the WHO from Bangladesh, Cambodia, Egypt and Indonesia, countries in which infections have also been reported in birds (Table I).
Antigenic and genetic characteristics
The nomenclature for phylogenetic relationships among the haemagglutinin (HA) genes of A(H5N1) viruses has been recently revised in consultation with representatives of WHO, the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and academic institutions. The updated nomenclature report will be published in the journal Influenza and Other Respiratory Viruses and on the WHO website.
Viruses circulating and characterized from 16 February to 19 September 2011 belonged to the following clades.
Clade 1.1 (previously part of clade 1) viruses were detected in poultry and humans in Cambodia and in poul try in Viet Nam. Genetic characterization of the HA genes of these viruses showed that they were closely related to clade 1.1 viruses that had circulated earlier in these countries. The HA genes from the viruses isolated from humans were located in 2 genetic groups (Figure 1); the human viruses reacted well with post-infection ferret antisera against the clade 1 viruses A/Viet Nam/1203/2004 and A/Viet Nam/1194/2004 from which candidate vaccine viruses have been developed (Table 5).
Clade 2.2.1 viruses continue to circulate in backyard poultry in Egypt with sporadic transmission to humans.
All recent human A(H5N1) viruses in Egypt belong to this clade (Figure 2). Clade 2.2.1 viruses were also detected in poultry in Israel. Viruses isolated during this period were genetically similar to those isolated previously. Recent human viruses reacted well with post- infection ferret antiserum against A/Egypt/N03072/2010 from which a candidate vaccine virus has been developed (Table 5).
Clade 2.2.1.1 (previously part of clade 2.2.1) viruses continued to circulate primarily within the commercial poultry sector in Egypt and were isolated from this population during the reporting period. Genetically these viruses were similar to other recent clade 2.2.1.1 viruses (Figure 2).
Clade 2.2.2 (previously part of clade 2.2) viruses were detected in poultry and humans in Bangladesh. Genetically these viruses were similar to viruses detected in this region in previous years (Figure 2). Post-infection ferret antisera against the clade 2.2 viruses A/chicken/ India/NIV33487/2006 and A/bar-headed goose/Qinghai Lake/1 A/2005, from which candidate vaccine viruses have been developed (Table 5), reacted well with the recent clade 2.2.2 viruses.
Clade 2.3.2.1 (previously part of clade 2.3.2) viruses were detected in wild birds in Bangladesh, Japan and the Republic of Korea, and also in poultry in Bangladesh, China Hong Kong Special Administrative Region (China Hong Kong SAR), India, Japan, Myanmar, Republic of Korea and Viet Nam. Although there is some genetic (Figure 3) and antigenic heterogeneity among viruses of this clade, recently isolated viruses reacted well with post-infection ferret antisera against either A/Hong Kong/6841/2010 (an A/Hubei/l/2010-like virus) or A/barn swallow/Hong Kong/D10-1161/2010 (Tables 2 and 3), from which candidate vaccine viruses have been developed (Table 5).
A Clade 2.3.4 virus was detected in a poultry carcass in China Hong Kong SAR. Antigenically and genetically this virus was similar to clade 2.3.4 viruses circulating in recent years (Figure 4).
Clade 2.3.4.2 (previously part of 2.3.4) viruses were detected in poultry in Bangladesh and Myanmar. Representative viruses from these countries were genetically similar to each other (Fig. 4) but showed reduced reactivity with post-infection ferret antisera against the clade 2.3.4 viruses A/chicken/Hong Kong/AP 156/2008, A/duck/Laos/3295/2006, and A/Japanese white eye/Hong Kong/1038/2006 (Table 4), from which candidate vaccine viruses have been developed (Table 5).
Influenza A(H5N1) candidate vaccine viruses
Based on the current antigenic, genetic and epidemiological data, development of a new clade 2.3.4.2 A/chicken/Bangladesh/llrsl984-30/2011-like candidate vaccine virus is proposed. The available candidate A(H5N1) vaccine viruses are listed in Table 5. On the basis of geographic spread, epidemiology and antigenic and genetic properties of the A(H5N1) viruses in particular locations, national authorities may consider theuse of one or more of these candidate vaccine viruses for pilot lot vaccine production, for clinical trials and other pandemic preparedness purposes.
As the viruses continue to evolve, new influenza A(H5N1) candidate vaccine viruses will be developed and announced as they become available. Institutions, companies and others who wish to receive these candidate vaccine viruses should contact WHO at gisrs- whohq@who.int or the institutions listed in announcements published on the WHO website.2
Influenza A(H9N2)
Influenza A(H9N2) viruses are enzootic in poultry populations in parts of Asia and the Middle East. Although characterization data on recent A(H9N2) viruses from many regions are limited, the majority of viruses that have been sequenced belong to the Gl clade or thechicken/Beijing (Y280/G9) clade. Since 1998, when the first human infection was detected, the isolation of A(H9N2) viruses from humans and swine has been reported infrequently. In all human cases the associated disease symptoms have been mild and there has been no evidence of human-to-human transmission.
Human influenza A(H9N2) infection: 16 February- September 2011
There has been one human case of A(H9N2) infection detected in Bangladesh in this reporting period. This
virus was genetically and antigenically similar to A(H9N2) viruses circulating in poultry in Bangladesh in previous years (Figure 5) but distinct from viruses from which candidate vaccine viruses have been developed (Table 6). Accordingly, the development of an A/Bangladesh/0994/2011-like candidate vaccine virus is proposed (Table 6).
As the viruses continue to evolve, new influenza A(H9N2) candidate vaccine viruses will be developed and announced as they become available. Institutions, companies and others who wish to receive these candidate vaccine viruses should contact WHO at gisrs-whohq@who.int or the institutions listed in announcements published on the WHO website.2
Swine-origin influenza A(H3N2)
Swine influenza A(H3N2) viruses are enzootic in swine herds of North America and other parts of the world. Characterization of recent A(H3N2) viruses from swine in North America indicates that their HA genes have evolved from the human virus precursors that circulated in the mid-1990s. Isolation of swine-origin influ- enza viruses (SOIV) A(H3N2) from humans has been reported infrequently. The United States reported 8 infections due to A(H3N2) SOIV between January 2005 and 15 February 2011.
A(H3N2) SOIV infections: 16 February to 19 September 2011
In the United States, there have been 4 human infections with A(H3N2) SOIV in the states of Indiana (1) and Pennsylvania (3) during this period. The HA and neuraminidase genes of these 4 viruses were similar to those of swine viruses that circulate in the United States. Sequencing data indicated that the matrix genes of these viruses were acquired from an A(HlNl)pdm09 virus, unlike SOIV isolates from previous human cases. Antigenic analysis indicated that these viruses were distinct from currently circulating human A(H3N2) viruses but similar to swine A(H3N2) viruses from previous years as well as to A/Minnesota/U/2010 (H3N2) SOIV (Table 7), from which a candidate vaccine virus is under development.
As the viruses continue to evolve, new SOIV candidate vaccine viruses will be developed and announced as they become available. Institutions, companies and others who wish to receive these candidate vaccine viruses should contact WHO at gisrs-whohq@who.int or the institutions listed in announcements published on the WHO website.2
Weekly Epidemiological Record (WER) 21 October 2011, vol. 86, 43 (pp 469?480)
Full text and tables: http://www.who.int/entity/wer/2011/wer8643.pdf
September 2011
The development of representative candidate influenza vaccine viruses, coordinated by WHO, remains an essential component of the overall global strategy for pandemic preparedness. Comparisons of the candidate vaccine viruses with respect to antigenicity and their relationship to newly emerging viruses are ongoing and will be periodically reported by WHO. An update of current and completed vaccine clinical trials can be found on the WHO web site.1
Influenza A(H5N1)
Since their re-emergence in 2003, highly pathogenic avian influenza A(H5N1) vi ruses have become enzootic in some coun tries and continue to cause outbreaks in poultry as well as sporadic human infections. The A(H5N1) viruses have diversified both genetically and antigenically leading to the need for multiple candidate vaccine viruses for pandemic prepared ness purposes. This summary provides updates on the characterization of A(H5N1) viruses isolated from birds and humans, and the current status of the development of candidate A(H5N1) vaccine viruses.
Influenza A(H5N1) activity:
16 February-19 September 2011
A{H5NI) viruses have been detected in birds in Africa, Asia, and the Middle East. Human infections have been reported to the WHO from Bangladesh, Cambodia, Egypt and Indonesia, countries in which infections have also been reported in birds (Table I).
Antigenic and genetic characteristics
The nomenclature for phylogenetic relationships among the haemagglutinin (HA) genes of A(H5N1) viruses has been recently revised in consultation with representatives of WHO, the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and academic institutions. The updated nomenclature report will be published in the journal Influenza and Other Respiratory Viruses and on the WHO website.
Viruses circulating and characterized from 16 February to 19 September 2011 belonged to the following clades.
Clade 1.1 (previously part of clade 1) viruses were detected in poultry and humans in Cambodia and in poul try in Viet Nam. Genetic characterization of the HA genes of these viruses showed that they were closely related to clade 1.1 viruses that had circulated earlier in these countries. The HA genes from the viruses isolated from humans were located in 2 genetic groups (Figure 1); the human viruses reacted well with post-infection ferret antisera against the clade 1 viruses A/Viet Nam/1203/2004 and A/Viet Nam/1194/2004 from which candidate vaccine viruses have been developed (Table 5).
Clade 2.2.1 viruses continue to circulate in backyard poultry in Egypt with sporadic transmission to humans.
All recent human A(H5N1) viruses in Egypt belong to this clade (Figure 2). Clade 2.2.1 viruses were also detected in poultry in Israel. Viruses isolated during this period were genetically similar to those isolated previously. Recent human viruses reacted well with post- infection ferret antiserum against A/Egypt/N03072/2010 from which a candidate vaccine virus has been developed (Table 5).
Clade 2.2.1.1 (previously part of clade 2.2.1) viruses continued to circulate primarily within the commercial poultry sector in Egypt and were isolated from this population during the reporting period. Genetically these viruses were similar to other recent clade 2.2.1.1 viruses (Figure 2).
Clade 2.2.2 (previously part of clade 2.2) viruses were detected in poultry and humans in Bangladesh. Genetically these viruses were similar to viruses detected in this region in previous years (Figure 2). Post-infection ferret antisera against the clade 2.2 viruses A/chicken/ India/NIV33487/2006 and A/bar-headed goose/Qinghai Lake/1 A/2005, from which candidate vaccine viruses have been developed (Table 5), reacted well with the recent clade 2.2.2 viruses.
Clade 2.3.2.1 (previously part of clade 2.3.2) viruses were detected in wild birds in Bangladesh, Japan and the Republic of Korea, and also in poultry in Bangladesh, China Hong Kong Special Administrative Region (China Hong Kong SAR), India, Japan, Myanmar, Republic of Korea and Viet Nam. Although there is some genetic (Figure 3) and antigenic heterogeneity among viruses of this clade, recently isolated viruses reacted well with post-infection ferret antisera against either A/Hong Kong/6841/2010 (an A/Hubei/l/2010-like virus) or A/barn swallow/Hong Kong/D10-1161/2010 (Tables 2 and 3), from which candidate vaccine viruses have been developed (Table 5).
A Clade 2.3.4 virus was detected in a poultry carcass in China Hong Kong SAR. Antigenically and genetically this virus was similar to clade 2.3.4 viruses circulating in recent years (Figure 4).
Clade 2.3.4.2 (previously part of 2.3.4) viruses were detected in poultry in Bangladesh and Myanmar. Representative viruses from these countries were genetically similar to each other (Fig. 4) but showed reduced reactivity with post-infection ferret antisera against the clade 2.3.4 viruses A/chicken/Hong Kong/AP 156/2008, A/duck/Laos/3295/2006, and A/Japanese white eye/Hong Kong/1038/2006 (Table 4), from which candidate vaccine viruses have been developed (Table 5).
Influenza A(H5N1) candidate vaccine viruses
Based on the current antigenic, genetic and epidemiological data, development of a new clade 2.3.4.2 A/chicken/Bangladesh/llrsl984-30/2011-like candidate vaccine virus is proposed. The available candidate A(H5N1) vaccine viruses are listed in Table 5. On the basis of geographic spread, epidemiology and antigenic and genetic properties of the A(H5N1) viruses in particular locations, national authorities may consider theuse of one or more of these candidate vaccine viruses for pilot lot vaccine production, for clinical trials and other pandemic preparedness purposes.
As the viruses continue to evolve, new influenza A(H5N1) candidate vaccine viruses will be developed and announced as they become available. Institutions, companies and others who wish to receive these candidate vaccine viruses should contact WHO at gisrs- whohq@who.int or the institutions listed in announcements published on the WHO website.2
Influenza A(H9N2)
Influenza A(H9N2) viruses are enzootic in poultry populations in parts of Asia and the Middle East. Although characterization data on recent A(H9N2) viruses from many regions are limited, the majority of viruses that have been sequenced belong to the Gl clade or thechicken/Beijing (Y280/G9) clade. Since 1998, when the first human infection was detected, the isolation of A(H9N2) viruses from humans and swine has been reported infrequently. In all human cases the associated disease symptoms have been mild and there has been no evidence of human-to-human transmission.
Human influenza A(H9N2) infection: 16 February- September 2011
There has been one human case of A(H9N2) infection detected in Bangladesh in this reporting period. This
virus was genetically and antigenically similar to A(H9N2) viruses circulating in poultry in Bangladesh in previous years (Figure 5) but distinct from viruses from which candidate vaccine viruses have been developed (Table 6). Accordingly, the development of an A/Bangladesh/0994/2011-like candidate vaccine virus is proposed (Table 6).
As the viruses continue to evolve, new influenza A(H9N2) candidate vaccine viruses will be developed and announced as they become available. Institutions, companies and others who wish to receive these candidate vaccine viruses should contact WHO at gisrs-whohq@who.int or the institutions listed in announcements published on the WHO website.2
Swine-origin influenza A(H3N2)
Swine influenza A(H3N2) viruses are enzootic in swine herds of North America and other parts of the world. Characterization of recent A(H3N2) viruses from swine in North America indicates that their HA genes have evolved from the human virus precursors that circulated in the mid-1990s. Isolation of swine-origin influ- enza viruses (SOIV) A(H3N2) from humans has been reported infrequently. The United States reported 8 infections due to A(H3N2) SOIV between January 2005 and 15 February 2011.
A(H3N2) SOIV infections: 16 February to 19 September 2011
In the United States, there have been 4 human infections with A(H3N2) SOIV in the states of Indiana (1) and Pennsylvania (3) during this period. The HA and neuraminidase genes of these 4 viruses were similar to those of swine viruses that circulate in the United States. Sequencing data indicated that the matrix genes of these viruses were acquired from an A(HlNl)pdm09 virus, unlike SOIV isolates from previous human cases. Antigenic analysis indicated that these viruses were distinct from currently circulating human A(H3N2) viruses but similar to swine A(H3N2) viruses from previous years as well as to A/Minnesota/U/2010 (H3N2) SOIV (Table 7), from which a candidate vaccine virus is under development.
As the viruses continue to evolve, new SOIV candidate vaccine viruses will be developed and announced as they become available. Institutions, companies and others who wish to receive these candidate vaccine viruses should contact WHO at gisrs-whohq@who.int or the institutions listed in announcements published on the WHO website.2
Weekly Epidemiological Record (WER) 21 October 2011, vol. 86, 43 (pp 469?480)
Full text and tables: http://www.who.int/entity/wer/2011/wer8643.pdf